MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 183 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NH3GRYpEgXSxdH;4bYMhSXO|YYm= NXTzeFZnOyEQvF2= NHz4Z|M4OiCq MVHEUXNQ MWTJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MmW2NlA2PzFyNkm=
A431 MknXT4lv[XOnIFHzd4F6 NHnJRYU2KM7:TR?= MmjIOUBp M4ruXmROW09? NHrGNoVUfXCycnXzd4V{KHSqZTDzbYdv[Wyrbnegc4YhSWu2IHHu[EBGemt? M4LiSlIxPTdzME[5
HepG2 NXmx[4w1S3m2b4TvfIlkKEG|c3H5 M1jYfVExKM7:TR?= Mon6NlQhcA>? MVXEUXNQ NHiyZXVU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> MWqyNVIxPTl{NR?=
Sk-Hep1 NFu5dWlEgXSxdH;4bYMhSXO|YYm= NXuzT|lmOTBizszN MXyyOEBp M4H5cWROW09? MofpV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni MlmyNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH4N{DPxE1? MnG4OUBl M3XBc2ROW09? NFjuTlJKSzVyPUCuNVQh|ryP MkHCNlEzQDl{Nke=
K1 cells harbored PIK3CA (E542K+/+) NV3MNmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvwN{DPxE1? MWe1JIQ> NUTCfnRMTE2VTx?= MkX6TWM2OD1yLkWyJO69VQ>? NGfVSpEzOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) NHK5[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL1[|kxOyEQvF2= MWC1JIQ> MVHEUXNQ NWroXmJWUUN3ME2wMlE5KM7:TR?= MlTFNlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−) M3;FNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L0R|Mh|ryP NE\BVnE2KGR? NGX1NVNFVVOR MlzNTWM2OD1yLkK3JO69VQ>? NEfN[m0zOTJ6OUK2Oy=>
Hth7 cells harbored NRAS (Q61R+/−) NWnKeldUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Z[FJMOyEQvF2= M4TBfVUh\A>? NVnsUJBSTE2VTx?= NUPCVGs1UUN3ME20MlUh|ryP Ml3MNlEzQDl{Nke=
TPC1 cells harbored RET/PTC1 rearrangement MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M360SlMh|ryP NHLrZ2U2KGR? M33nemROW09? MUDJR|UxRTBwNUmg{txO MmjyNlEzQDl{Nke=
Hth74 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGzJO69VQ>? M1u0VlUh\A>? NG\EcZJFVVOR M3jIbGlEPTB;Mj6xPUDPxE1? MnzVNlEzQDl{Nke=
KAT18 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;QT|Mh|ryP MWC1JIQ> MlXUSG1UVw>? M3raemlEPTB;ND62NkDPxE1? NWf0TYlpOjF{OEmyOlc>
SW1736 M1\mTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkntNVAxKM7:TR?= NXjMcJRkPSCm MoHwSG1UVw>? NVm4bYk1UUN3ME20O{42PiEQvF2= MWCyNVI5QTJ4Nx?=
WRO M{HuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES3S5MyODByIN88US=> MVq1JIQ> NYOzXXJWTE2VTx?= NIrwRYhKSzVyPkGwNFAh|ryP NXXEUmM6OjF{OEmyOlc>
TAD2 NEflcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq4b5NlOTByMDFOwG0> MmHiOUBl MXfEUXNQ NETUdW9KSzVyPkGwNFAh|ryP NYrhXI1OOjF{OEmyOlc>
LN229 MYjBdI9xfG:|aYOgRZN{[Xl? MlTPNE42KM7:TR?= MorvOlAhcA>? NYC1Ums{TE2VTx?= Moe5RZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? M3m5ZVIzODV5OUG0
T98G M2HsU2Fxd3C2b4Ppd{BCe3OjeR?= MmT6NE42KM7:TR?= M1P6O|YxKGh? NFO5NplFVVOR NWrRUo85SXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= M{[4SFIzODV5OUG0
HC11 MXvGeY5kfGmxbjDBd5NigQ>? NWrrcXVZOTBizszN NXLJdZZ4OjRiaB?= MljCSG1UVw>? MkP5TY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> M3ewOVIzPDJ4NkKx
MOLT-4 NVLmeI1RS3m2b4TvfIlkKEG|c3H5 MYqxNEDPxE1? MVS0PEBp Mn3mSG1UVw>? M3X3c2lEPTB;MT635qCK|ryP NIe4[4YzOjZzNEK0Ny=>
CEM-R NFm1bJREgXSxdH;4bYMhSXO|YYm= M{HYflExKM7:TR?= MkP6OFghcA>? NX\vVItxTE2VTx?= NH:5OXdKSzVyPUOuN-KBkc7:TR?= NUn0boliOjJ4MUSyOFM>
CEM-S NHHsWlhEgXSxdH;4bYMhSXO|YYm= MXSxNEDPxE1? NYD4dolDPDhiaB?= M1G3OGROW09? MXvJR|UxRTVwMfMAje69VQ>? NUThT25mOjJ4MUSyOFM>
MOLT-4 M4C3OmZ2dmO2aX;uJGF{e2G7 MWqxNEDPxE1? MoLBNlQhcA>? NX3rUnk{TE2VTx?= MVTCcI9kc3NiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNmKG:oIITo[UBk\WyuIHP5Z4xm MoLqNlI3OTR{NEO=
MOLT-4 NIW5d|BHfW6ldHnvckBCe3OjeR?= MorqOQKBkc7:TR?= MUK0JIg> MnXMSG1UVw>? M2LDTGlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFOzRU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? NVS0T|V7OjJ4MUSyOFM>
CEM-R MVHGeY5kfGmxbjDBd5NigQ>? NGqwdZk16oDLzszN NWmwdJFzPCCq MXLEUXNQ MmixTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz NFPZc4EzOjZzNEK0Ny=>
CEM-S MXPGeY5kfGmxbjDBd5NigQ>? M{L0[FTjiIoQvF2= NFX2[XY1KGh? NELxXGFFVVOR NIHHW2ZKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? M4rSbVIzPjF2MkSz
HepG2 cell Mn;aT4lv[XOnIFHzd4F6 MmDINlAh|ryP NESx[YwzPCCq NVHxSFN2TE2VTx?= MU\Ec5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV M4\peVI{Pzl5M{G5
HepG2 cell NVXXSmhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXn[3E{OCEQvF2= NHP4V4gzPCCq NY\5TIJUTE2VTx?= NIGzTodKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MmXBNlM4QTd|MUm=
HepG2 cell NFzZXHVCeG:ydH;zbZMhSXO|YYm= MnXGNlAh|ryP M1jwOFI1KGh? NX3jb5ZJTE2VTx?= MUDJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFLmSIIzOzd7N{OxPS=>
GEO NXfPOZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzTOVAxKG6P M{O2SVczKGh? MYXEUXNQ NIq2UnpKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NF\jepEzPDV6MUKzNS=>
CNE-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNEDPxE1? NYHmbHpQQTZiaB?= NHHUcI1FVVOR NWLOe4pMUUN3ME2yMlk3KM7:TR?= M4rCcVI2OzN4OUK1
CNE-2 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jaOlExKM7:TR?= M1[xNFk3KGh? MX3EUXNQ M1HKV2lEPTB;ND61N{DPxE1? MVOyOVM{Pjl{NR?=
HONE-1 NFfydlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\PN|MyOTBizszN MnT0PVYhcA>? M3HTcWROW09? NYPGd5BVUUN3ME2zMlM4KM7:TR?= M17tVVI2OzN4OUK1
SUNE-1 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHDNVAh|ryP M2nkXlk3KGh? MXHEUXNQ NIDUVZRKSzVyPUCuOVIh|ryP MlS3NlU{OzZ7MkW=
CNE-2 NHT5W5BHfW6ldHnvckBCe3OjeR?= MYGxNEDPxE1? NE[1WXk1QCCq NEjSfW5FVVOR NXPUfpRZUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= MYeyOVM{Pjl{NR?=
HONE-1 MXfGeY5kfGmxbjDBd5NigQ>? NYr5RpdGOTBizszN NGPUWVg1QCCq MlnJSG1UVw>? NEiwSodKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MonvNlU{OzZ7MkW=
NEC8 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rzd2lEPTB;MD6wPVY2OSEQvF2= NWrLepB4W0GQR1XS
P12-ICHIKAWA NGnOUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOxO3VKSzVyPUCuNVE3OiEQvF2= NELvZo9USU6JRWK=
MDA-MB-175-VII MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm0[|BKSzVyPUCuNVM4OzhizszN NX7u[2U2W0GQR1XS
AsPC-1 M4jaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLBZWpKSzVyPUCuNlIyOjJizszN NEGwco1USU6JRWK=
T47D M{LjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rHcGlEPTB;MD6yPFI2KM7:TR?= MkH1V2FPT0WU
HH Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK5eW1KSzVyPUCuN|AzQDNizszN NE\jZYRUSU6JRWK=
MOLT-16 NHfsRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjuR3ZYUUN3ME2wMlMxOzJizszN MV\TRW5ITVJ?
ES5 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvvdmZKSzVyPUCuN|Q1PTVizszN M1i0SHNCVkeHUh?=
RS4-11 NFr4fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULn[IFVUUN3ME2wMlM1PjFizszN MVPTRW5ITVJ?
KARPAS-45 NVmxPHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPFbFl[UUN3ME2wMlM4OzJzIN88US=> MYHTRW5ITVJ?
NCI-H720 NGqwZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrH[FRiUUN3ME2wMlM4Pjd7IN88US=> NXuwcnNRW0GQR1XS
H9 NHzKN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXTWM2OD1yLkO4PFg{KM7:TR?= MmnnV2FPT0WU
EFM-19 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;6emlEPTB;MD60OFAyKM7:TR?= NHTKUJpUSU6JRWK=
SBC-1 M2Sw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v1OmlEPTB;MD60OFA{PSEQvF2= MoLJV2FPT0WU
A4-Fuk MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\QTWM2OD1yLkS2PFY5KM7:TR?= MXPTRW5ITVJ?
NCI-H1563 M3v0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12zc2lEPTB;MD60PFE5QSEQvF2= MojFV2FPT0WU
HCC1419 M4\rU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu3OGRYUUN3ME2wMlQ5QDl{IN88US=> MV;TRW5ITVJ?
H-EMC-SS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwNEm5N|kh|ryP NVPlNZNMW0GQR1XS
BHT-101 NHvxcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;yTItIUUN3ME2wMlUzQTZzIN88US=> MU\TRW5ITVJ?
IGROV-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnhTWM2OD1yLkW1NlQ6KM7:TR?= MYrTRW5ITVJ?
HGC-27 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH73OGpKSzVyPUCuOVY4QDNizszN Mnz4V2FPT0WU
MDA-MB-361 M2[3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zWe2lEPTB;MD61O|c3OSEQvF2= MVrTRW5ITVJ?
KE-37 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;EfpdKSzVyPUCuOVgzPiEQvF2= MlXnV2FPT0WU
HCC70 NGWxTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu4TWM2OD1yLkW5PFI4KM7:TR?= Mk\tV2FPT0WU
LNCaP-Clone-FGC M4DZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnXcmZKSzVyPUCuOlExPDhizszN NI\wT2tUSU6JRWK=
HAL-01 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNkKxN{DPxE1? MkLLV2FPT0WU
HT MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH71TW1KSzVyPUCuOlMzOzlizszN M4LSXHNCVkeHUh?=
MDA-MB-415 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmwTWM2OD1yLk[zOlI3KM7:TR?= MYHTRW5ITVJ?
NOS-1 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVeyc5FsUUN3ME2wMlY{PzJ|IN88US=> NXiwRXM6W0GQR1XS
DU-145 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni4TWM2OD1yLk[0O|Q2KM7:TR?= NELhZ5BUSU6JRWK=
OCUB-M M{HtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmflTWM2OD1yLkewPVY3KM7:TR?= MnrqV2FPT0WU
VA-ES-BJ M4nIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGbGFzUUN3ME2wMlc{ODJ3IN88US=> MoCyV2FPT0WU
J-RT3-T3-5 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle3TWM2OD1yLke0OFA{KM7:TR?= Mo[xV2FPT0WU
MOLT-4 NX\pT3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TYeGlEPTB;MD64NFU5OiEQvF2= Mkn2V2FPT0WU
NB7 NUXBTlljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fmZ2lEPTB;MD64NlQyOSEQvF2= MorvV2FPT0WU
L-363 NEnQRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PxRWlEPTB;MD64N|Q1OiEQvF2= NIHkRYdUSU6JRWK=
NKM-1 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j1SmlEPTB;MD64OlI2OyEQvF2= MWTTRW5ITVJ?
HOP-92 NVPRZnd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6zTWM2OD1yLki3NlI{KM7:TR?= NUD6cIh5W0GQR1XS
OAW-42 M3nzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH31RYFKSzVyPUCuPFg4OiEQvF2= MXPTRW5ITVJ?
HuO9 M4DkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfVfXJrUUN3ME2wMlkzPzVzIN88US=> MkPIV2FPT0WU
MFE-280 NFWwb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjvTWM2OD1yLkm2OFY2KM7:TR?= M4rPPHNCVkeHUh?=
EM-2 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwOUe5N|kh|ryP MX\TRW5ITVJ?
NCI-H520 NFjFSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwOUi1PVIh|ryP M4XsZnNCVkeHUh?=
LB2241-RCC M{n6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwOUm3N|Qh|ryP NHfaVIZUSU6JRWK=
SK-NEP-1 NEK0U3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwMUS0PFUh|ryP NWnYd3d7W0GQR1XS
LXF-289 NUXEdoZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD1zLkG3NVU3KM7:TR?= NHH4TZJUSU6JRWK=
EPLC-272H NV\hTZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6yfG9WUUN3ME2xMlE4OjV4IN88US=> M4\URXNCVkeHUh?=
COLO-684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTDVGxiUUN3ME2xMlI{PzJ3IN88US=> MYjTRW5ITVJ?
ES1 NF[5b21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjUc2U5UUN3ME2xMlI1ODZ3IN88US=> MnLkV2FPT0WU
DOHH-2 NXTEV5BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLzWmZKSzVyPUGuNlgzODNizszN M3WxeXNCVkeHUh?=
CTB-1 NEntV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHuTWM2OD1zLkK4PVkh|ryP M{\Xb3NCVkeHUh?=
G-401 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTFV41KUUN3ME2xMlI6Pzl3IN88US=> NFvYZmtUSU6JRWK=
LoVo NGfscnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwM{K1N|Qh|ryP M2rFUHNCVkeHUh?=
Ramos-2G6-4C10 M1H2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD4b|hvUUN3ME2xMlM{PzBzIN88US=> M4K5O3NCVkeHUh?=
MFM-223 NGTaSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DpeGlEPTB;MT6zOFQ3OSEQvF2= NWHoSHRIW0GQR1XS
PA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHOTWM2OD1zLkO1NlY2KM7:TR?= NUnNdXR4W0GQR1XS
697 M3H1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwM{e2NVYh|ryP MkXsV2FPT0WU
QIMR-WIL M4DDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XYSmlEPTB;MT60PVEyPiEQvF2= MYHTRW5ITVJ?
HOS NYTP[2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n6Z2lEPTB;MT60PVU2QCEQvF2= MX;TRW5ITVJ?
DMS-273 NYP2WmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzOTWM2OD1zLkWxPVU6KM7:TR?= NHuwVWpUSU6JRWK=
ME-180 NUfme4dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0cW5KSzVyPUGuOVY5QTFizszN MYnTRW5ITVJ?
HCC2218 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnPTWM2OD1zLk[4NlI2KM7:TR?= NWLpNo5lW0GQR1XS
CAL-54 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT2U|ZKSzVyPUGuO|EzPDJizszN NE\GN3BUSU6JRWK=
OMC-1 NIT2UJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;XTWM2OD1zLke0Olc4KM7:TR?= NGPwPG9USU6JRWK=
COR-L105 NYXHUJNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm2b|BGUUN3ME2xMlc6PzN5IN88US=> NXr6cXN4W0GQR1XS
BV-173 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq5Tow1UUN3ME2xMlgyODd2IN88US=> M{T3[HNCVkeHUh?=
RKO MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDtVZkxUUN3ME2xMlg4OTBzIN88US=> NW\kOGs2W0GQR1XS
SNU-387 NUTrfZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTZPZNPUUN3ME2xMlg5PDB4IN88US=> M4XVfnNCVkeHUh?=
SW1088 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rsVGlEPTB;MT65OFYxPiEQvF2= NWPq[|N[W0GQR1XS
Hs-578-T NH;Ue2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO4O4s6UUN3ME2yMlEyPDN|IN88US=> MYTTRW5ITVJ?
OC-314 NX2xbZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G3WWlEPTB;Mj6xOVA5PiEQvF2= NXL1eZFZW0GQR1XS
RMG-I MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzhfIFvUUN3ME2yMlE3Ozl6IN88US=> NHjaWXFUSU6JRWK=
NCI-H1395 NFTib2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPibpJKSzVyPUKuNVgxQTFizszN NUe4cWFZW0GQR1XS
GAMG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDHTWM2OD1{LkKzPFQ2KM7:TR?= NVq4dJJQW0GQR1XS
LB1047-RCC Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJwMkSzNVch|ryP NV3KUoJHW0GQR1XS
MN-60 NUHxWo53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwMkm5NlMh|ryP NIT6OHNUSU6JRWK=
OAW-28 NWL3[lQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX1TWM2OD1{LkK5PVUyKM7:TR?= Mlf2V2FPT0WU
NCI-H2228 NUjXUIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHLTWM2OD1{LkOxOVUzKM7:TR?= NGDBZY5USU6JRWK=
ABC-1 NELpdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPJWIZKSzVyPUKuN|MzPTNizszN NHfLcJdUSU6JRWK=
LS-513 M1LPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm2WFlKSzVyPUKuN|M1QDRizszN NXjj[IxXW0GQR1XS
KS-1 NVXnVZdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP2ZpJ6UUN3ME2yMlM5OTlzIN88US=> NEmwPFBUSU6JRWK=
NB69 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwM{i5PFMh|ryP NX3HeFFsW0GQR1XS
VM-CUB-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnoTWM2OD1{LkO5NFg{KM7:TR?= M1;Qb3NCVkeHUh?=
D-423MG NVK3TVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvpTWM2OD1{LkSxNFQ1KM7:TR?= MoHlV2FPT0WU
EW-18 NY\GToh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjjOnF7UUN3ME2yMlQyQTN7IN88US=> NH\kTYlUSU6JRWK=
YH-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjkT5pJUUN3ME2yMlQ3OTV|IN88US=> NXLlU|JuW0GQR1XS
T-24 NUe4eo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWixSIxWUUN3ME2yMlQ4QDhzIN88US=> MX;TRW5ITVJ?
ES8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJwNEmyPFch|ryP NEnxUYlUSU6JRWK=
ES3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz5S3FKSzVyPUKuOFk4PTlizszN NYHmcIYyW0GQR1XS
RXF393 NF;YSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPCdlc4UUN3ME2yMlYxPDh5IN88US=> NX7ZdlFZW0GQR1XS
RPMI-8226 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTHWlVKUUN3ME2yMlYzQTV|IN88US=> NE\0S29USU6JRWK=
AGS NEe5c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmxTWM2OD1{LkeyNVM4KM7:TR?= NF[zXm1USU6JRWK=
HCC1395 NGCxWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvyPI5DUUN3ME2yMlc2OTh5IN88US=> NVLlbGNiW0GQR1XS
MV-4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwN{WyOlYh|ryP M3HpeHNCVkeHUh?=
A204 M3;jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP5RXFKSzVyPUKuPFM5PzJizszN MYnTRW5ITVJ?
MCF7 NHTnSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwOE[xNVch|ryP MYDTRW5ITVJ?
SNU-423 M{myVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXBN5IzUUN3ME2yMlg6OjR{IN88US=> NX;FXmw2W0GQR1XS
NCI-H1048 NHLyZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4XYNVUUN3ME2yMlk3QDZ3IN88US=> M33yenNCVkeHUh?=
GR-ST MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjwc5hYUUN3ME2zMlA1PjFzIN88US=> NFnITXJUSU6JRWK=
EoL-1- MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNwMEewOVgh|ryP MnHpV2FPT0WU
HuH-7 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC5bHNyUUN3ME2zMlA6PDZ2IN88US=> NILoU5BUSU6JRWK=
OS-RC-2 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z5eWlEPTB;Mz6xNVE6KM7:TR?= Mn7DV2FPT0WU
EW-3 NFnRNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP4[ZBOUUN3ME2zMlE6PTJ7IN88US=> MVTTRW5ITVJ?
NCI-H747 NUHve4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjS[oVKSzVyPUOuNlA3QTRizszN MnfLV2FPT0WU
EW-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMkG4O|kh|ryP NGrjOJlUSU6JRWK=
DOK MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nqRmlEPTB;Mz6yNlg2QSEQvF2= NYPSNWl6W0GQR1XS
HCC2157 NI\k[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5b2tSUUN3ME2zMlM5OTd7IN88US=> MojxV2FPT0WU
OVCAR-3 NFHXZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\sWmlEPTB;Mz60NFc5PiEQvF2= NXf0SJFGW0GQR1XS
NCI-H1623 NUfFfGNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjwNYNKSzVyPUOuOFEzOjRizszN Mm\aV2FPT0WU
H4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwNEW2NlYh|ryP M1zwN3NCVkeHUh?=
SW1710 NFfYbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHmXYZqUUN3ME2zMlQ3Pjd6IN88US=> M17xb3NCVkeHUh?=
RT-112 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonUTWM2OD1|LkWyN|g5KM7:TR?= NF\FNG5USU6JRWK=
DMS-114 NVnQN2NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPGVYhXUUN3ME2zMlYzOjd6IN88US=> NVjpcIxUW0GQR1XS
AN3-CA NVjiZWViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLST|JKSzVyPUOuOlI1PTZizszN MXzTRW5ITVJ?
KNS-62 NVTocpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj2TWM2OD1|Lk[zN|M5KM7:TR?= NWPrNYR3W0GQR1XS
SJRH30 NVz0U5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXjSnVXUUN3ME2zMlY6OTJ{IN88US=> MYfTRW5ITVJ?
G-402 NH[5S5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrM[HlKSzVyPUOuO|A4OTFizszN M1XROHNCVkeHUh?=
MHH-PREB-1 NUjzXmdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzXdIpKSzVyPUOuO|IxOzhizszN MYTTRW5ITVJ?
P30-OHK NIDtOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV36SJN3UUN3ME2zMlgxQTd4IN88US=> MXLTRW5ITVJ?
RVH-421 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPGTWM2OD1|LkixO|g5KM7:TR?= M{[3fnNCVkeHUh?=
LU-134-A NFK0dWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvtcJpKSzVyPUOuPFg1OjhizszN MnG0V2FPT0WU
ECC10 M3nSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTMTWM2OD1|LkmzOlIzKM7:TR?= NX;FXVdYW0GQR1XS
TGW M3jobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwMEKzNFUh|ryP MoXMV2FPT0WU
MLMA NEW0SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuxZ5VKSzVyPUSuNFI6PjZizszN Mn3WV2FPT0WU
SCC-25 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:yTWM2OD12LkC2OVY3KM7:TR?= MnrYV2FPT0WU
TYK-nu NVjqUmJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SxV2lEPTB;ND6wPVU{PCEQvF2= Mnn5V2FPT0WU
LAMA-84 M4\mUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGNGlEPTB;ND6xOFE6OSEQvF2= MUfTRW5ITVJ?
Calu-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yRWlEPTB;ND6yOFQyPiEQvF2= NFe0fHJUSU6JRWK=
NCI-H460 NELrVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwMk[0OFMh|ryP NUTENYU5W0GQR1XS
EGI-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jURWlEPTB;ND6zO|c4QCEQvF2= M2Lzd3NCVkeHUh?=
NCI-H292 M2LuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\3TWM2OD12LkO4NVQ3KM7:TR?= NVTVSms4W0GQR1XS
HCE-T NYC4dm1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\oUWlEPTB;ND60NVU4QSEQvF2= MVjTRW5ITVJ?
EW-11 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LFcGlEPTB;ND60NVg{QCEQvF2= NVvpbIhNW0GQR1XS
ATN-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonJTWM2OD12LkS0N|A1KM7:TR?= NWrld4N1W0GQR1XS
NB5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRwNUO2PVch|ryP NFXteYZUSU6JRWK=
KLE MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwN{CxPVgh|ryP NGDafVBUSU6JRWK=
CAL-39 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TJZWlEPTB;ND63NlE1PiEQvF2= MnfwV2FPT0WU
TI-73 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe1TWM2OD12LkiwOlA6KM7:TR?= M37xR3NCVkeHUh?=
HO-1-N-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHxW|Z{UUN3ME20Mlk1OiEQvF2= NVzuVIN7W0GQR1XS
786-0 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHQTWM2OD12Lkm0Olc{KM7:TR?= Mnu2V2FPT0WU
SK-N-DZ M3\2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfRTWM2OD12Lkm2NVQzKM7:TR?= MlvLV2FPT0WU
NCI-H446 NYjLOll5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\WTWM2OD13LkKwNFA6KM7:TR?= NU\MbWJzW0GQR1XS
ETK-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLqTWM2OD13LkKxNVY2KM7:TR?= M1noenNCVkeHUh?=
BT-20 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXUNo1KSzVyPUWuNlE{PTNizszN Mo\ZV2FPT0WU
MEL-HO Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvWTmRKSzVyPUWuN|c{OzZizszN NF;ENIJUSU6JRWK=
CAL-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;DV2lEPTB;NT60OlM{QSEQvF2= NWrEPVY1W0GQR1XS
SW872 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrBbmFFUUN3ME21MlU6PDJ6IN88US=> NYrsfHM1W0GQR1XS
RPMI-2650 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTVwNk[xPVkh|ryP MYnTRW5ITVJ?
PFSK-1 NYrhd29{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTVwN{K3N|Ih|ryP M3vZbXNCVkeHUh?=
SF295 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwOEC2N|Mh|ryP MkO4V2FPT0WU
Becker MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTVwOE[0O|Ih|ryP NXzDUZg3W0GQR1XS
Saos-2 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjyWVJKSzVyPUWuPFY2OyEQvF2= NEi2eHBUSU6JRWK=
SK-OV-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7oNpJKSzVyPUWuPVk5OTZizszN M37iWnNCVkeHUh?=
VMRC-RCZ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X0bWlEPTB;Nj6wPFc4OyEQvF2= MlvxV2FPT0WU
EW-22 M{XR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnibnZXUUN3ME22MlE6PjR7IN88US=> M321UHNCVkeHUh?=
BT-474 M1[zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT6TWM2OD14LkKzN{DPxE1? Ml;2V2FPT0WU
BFTC-909 NVj0[FZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILaTJZKSzVyPU[uN|A{PDVizszN M2LVTXNCVkeHUh?=
NB12 NFzabWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwM{mwO|Eh|ryP MljFV2FPT0WU
D-263MG M3q4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBd5VKSzVyPU[uOFUyPjlizszN MVjTRW5ITVJ?
SNB75 NV7N[FdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZwNkCxOFMh|ryP NUjTU2xtW0GQR1XS
A704 M{\wTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PUbmlEPTB;Nj62N|A3KM7:TR?= NXPEV4RZW0GQR1XS
NCI-H1693 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL3VG96UUN3ME22MlY{PjB2IN88US=> NITwdW5USU6JRWK=
LN-405 M{DESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW1[W5KSzVyPU[uO|k3PzJizszN Mk\QV2FPT0WU
CHL-1 M3Xqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwOECwO|kh|ryP Mm\YV2FPT0WU
A498 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnBUVBHUUN3ME22MlgyQTZzIN88US=> MmWzV2FPT0WU
TE-12 M3\R[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPKTWM2OD14LkizPFE4KM7:TR?= NY\UTIo5W0GQR1XS
TE-6 NGTxZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\pNmlEPTB;Nj65N|A{QCEQvF2= MmjlV2FPT0WU
AU565 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnJT4xKSzVyPU[uPVY6PTdizszN M33LSHNCVkeHUh?=
RD MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z5b2lEPTB;Nj65PFI5PCEQvF2= MlPPV2FPT0WU
SW1463 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTdwMUGxOlgh|ryP MkLVV2FPT0WU
LU-99A Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTdwMUSzNlIh|ryP MnrlV2FPT0WU
NCI-H28 M2jpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwMkmyOEDPxE1? M2DqO3NCVkeHUh?=
MC-IXC NH\qUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;afZdtUUN3ME23MlQ5PTd4IN88US=> MkO0V2FPT0WU
GP5d MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\admRUUUN3ME23MlQ5PzZ2IN88US=> MYDTRW5ITVJ?
GB-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGzTYR4UUN3ME23MlU1QDB2IN88US=> NYX3UJlZW0GQR1XS
CAL-33 M2PjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjKWmxxUUN3ME23MlY3OjN|IN88US=> M1HjcXNCVkeHUh?=
MSTO-211H MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TQc2lEPTB;Nz62O|M{PiEQvF2= M1LCVnNCVkeHUh?=
TE-5 NXrPR3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ETWM2OD15Lke5N|M1KM7:TR?= Ml21V2FPT0WU
D-566MG NEXH[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknFTWM2OD16LkC0OFI6KM7:TR?= M1yxS3NCVkeHUh?=
JVM-3 M1nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRThwMUWyOlgh|ryP NYHFdYlLW0GQR1XS
T98G NWjiPI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3GTWM2OD16LkG4NFY4KM7:TR?= Mlr2V2FPT0WU
HCC1954 M331V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRThwNEWxNFQh|ryP NG\2WINUSU6JRWK=
SF126 NXH0T3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XMVmlEPTB;OD60OVk{PiEQvF2= NFrqOIlUSU6JRWK=
LB996-RCC NEe4NZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rMd2lEPTB;OD61N|I2PyEQvF2= MX3TRW5ITVJ?
SKG-IIIa MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzXTWM2OD16Lk[zNFY6KM7:TR?= NHezVVdUSU6JRWK=
NCI-SNU-1 NFm1dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnjWlRKSzVyPUiuOlQ3PDNizszN MofpV2FPT0WU
LB771-HNC NFXQZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDU[ZBKSzVyPUiuOlQ3QTZizszN NEm1[ZpUSU6JRWK=
SCC-4 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XPO2lEPTB;OD62PFIyQSEQvF2= NWDVOGxoW0GQR1XS
CAMA-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqxXJZKSzVyPUiuO|cyPDZizszN NGHyOGJUSU6JRWK=
D-502MG NHXTeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRThwN{i2Nlkh|ryP NH20SHFUSU6JRWK=
ESS-1 NGjUNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P0RmlEPTB;OD64PFcxPCEQvF2= MXTTRW5ITVJ?
HEC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrmTWM2OD16Lki5PFY3KM7:TR?= M{DWTXNCVkeHUh?=
NB10 NHPaVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHHTWM2OD17LkCyNlI1KM7:TR?= M3L5OHNCVkeHUh?=
8505C MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfKZopKSzVyPUmuNFQzOzJizszN MlLLV2FPT0WU
EFO-27 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTnepNSUUN3ME25MlE3PDF{IN88US=> NFLLZYhUSU6JRWK=
HN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\WfGNKSzVyPUmuNVY3OjhizszN NF3wbVdUSU6JRWK=
DSH1 NF\JeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHRTWM2OD17LkKwPFch|ryP M4S1cXNCVkeHUh?=
NBsusSR M{HLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH3TWM2OD17LkK3OFAzKM7:TR?= NXPOcVhCW0GQR1XS
LS-123 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTlwM{G3OlEh|ryP MVjTRW5ITVJ?
SHP-77 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTlwM{m5N|Uh|ryP NX;qeGZvW0GQR1XS
ACN MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\rVldKSzVyPUmuOVMzPzdizszN NGq4W3RUSU6JRWK=
U251 NVO3NXBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnhcldNUUN3ME25MlY2PTR2IN88US=> MU\TRW5ITVJ?
A431 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lhc2lEPTB;OT64NFI{QCEQvF2= NYDKOIw4W0GQR1XS
5637 M1rU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LMemlEPTB;OT64OFk5PCEQvF2= MojyV2FPT0WU
MDA-MB-157 NUjNR4g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LlXGlEPTB;OT65Nlg4QCEQvF2= M1:5TnNCVkeHUh?=
A101D NX7XUFBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[zS2lKSzVyPUmuPVk6PzRizszN NXPsSnZLW0GQR1XS
YKG-1 M4mzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjzTWM2OD1zMD6yNFA3KM7:TR?= Mm\DV2FPT0WU
LAN-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDpNYFTUUN3ME2xNE4zOTZ2IN88US=> MVvTRW5ITVJ?
OVCAR-5 NVG4SFJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljsTWM2OD1zMD6yOFM{KM7:TR?= M4rvRnNCVkeHUh?=
A549 NE\Ic2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFyLkO5O|Mh|ryP MXrTRW5ITVJ?
no-11 M4[4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFyLkSzOVMh|ryP M1G4e3NCVkeHUh?=
SF539 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHuT5ZKSzVyPUGwMlkxPDFizszN NGnJVFdUSU6JRWK=
A388 NFHrVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH5TWM2OD1zMT6zPFk4KM7:TR?= MkjQV2FPT0WU
DEL NYjCTY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjwdnNKSzVyPUGxMlQzPCEQvF2= NHThU49USU6JRWK=
SW954 M3LHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHUTWM2OD1zMT60OlY5KM7:TR?= MlrLV2FPT0WU
TK10 M3PBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCwTWM2OD1zMT61NlcyKM7:TR?= M3zudnNCVkeHUh?=
SW756 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LnbWlEPTB;MUGuOVI6PCEQvF2= MUTTRW5ITVJ?
PC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LpU2lEPTB;MUGuOVc3PCEQvF2= NI\uXlBUSU6JRWK=
ONS-76 NVPsfnozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD1zMT62N|Yh|ryP M1;hOHNCVkeHUh?=
A427 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFzLkewPVMh|ryP MoThV2FPT0WU
MEG-01 NUDnfllRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfDVpRYUUN3ME2xNU44PTB7IN88US=> NVzRXXpLW0GQR1XS
BB30-HNC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3Hb2NKSzVyPUGxMlc6QDJizszN NYH2XGJHW0GQR1XS
NCI-H1299 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED5PFJKSzVyPUGxMlgxQTNizszN MULTRW5ITVJ?
GCT NUe5[VAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkiyNlgh|ryP M{HURnNCVkeHUh?=
D-247MG NVTsbphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnibZlrUUN3ME2xNU46PjZ|IN88US=> NIfE[XpUSU6JRWK=
CFPAC-1 NVH6TW41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn6TWM2OD1zMT65O|gzKM7:TR?= MoDLV2FPT0WU
EKVX M4Kzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfHTWM2OD1zMj6wN|E{KM7:TR?= MV7TRW5ITVJ?
CAL-51 NWPGUldkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTxTWM2OD1zMj6wO|E3KM7:TR?= NXryNnBTW0GQR1XS
BB49-HNC M2Ljemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XRRmlEPTB;MUKuNVE4PyEQvF2= NH\BcIRUSU6JRWK=
RPMI-7951 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjbmlEPTB;MUKuNVg2PCEQvF2= NWW1S2x1W0GQR1XS
RH-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHieFRKSzVyPUGyMlIyQDRizszN NV[zZ3h1W0GQR1XS
BCPAP NFy4OIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXoSZljUUN3ME2xNk41PzR7IN88US=> MmLiV2FPT0WU
GCIY NGnC[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXHTWM2OD1zMj61NlA6KM7:TR?= NF:5[lFUSU6JRWK=
KNS-81-FD M1HLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHrTWM2OD1zMj61PFY6KM7:TR?= MVzTRW5ITVJ?
KYSE-140 NGK1W|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{Lki1PVUh|ryP NEjqVndUSU6JRWK=
Ca-Ski MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j0e2lEPTB;MUKuPVA1OSEQvF2= NYPDOYw4W0GQR1XS
TGBC1TKB MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP5TWM2OD1zMj65NVE2KM7:TR?= Mo\tV2FPT0WU
HCC1187 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2zRlBXUUN3ME2xN{4yQTF{IN88US=> MVPTRW5ITVJ?
SJSA-1 NVmxXFFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqwTWM2OD1zMz6yN|I4KM7:TR?= MXXTRW5ITVJ?
CTV-1 M3i0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3vbXBKSzVyPUGzMlM1PSEQvF2= M4TZZXNCVkeHUh?=
WM-115 M3f2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF|Lk[0PFMh|ryP NXzxdmQ6W0GQR1XS
CHP-212 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF|Lkm3N|kh|ryP NFrD[GVUSU6JRWK=
SCC-15 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF|Lkm3O|Uh|ryP M{Du[XNCVkeHUh?=
BPH-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGwUpNHUUN3ME2xOE4yPjZ2IN88US=> MYTTRW5ITVJ?
SW780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\BN4psUUN3ME2xOE42ODJ3IN88US=> NWLj[oVOW0GQR1XS
NCI-H2291 M1Xtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:5SYlYUUN3ME2xOE42QDd6IN88US=> MVrTRW5ITVJ?
JEG-3 NU[4U4piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLhVFVRUUN3ME2xOE43OzJ4IN88US=> NEnXXHdUSU6JRWK=
CAL-120 NWDaO5hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{noe2lEPTB;MUSuO|AzPyEQvF2= M2Xs[nNCVkeHUh?=
NCI-H23 MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnh[lBxUUN3ME2xOE44QTl5IN88US=> M2fRNXNCVkeHUh?=
MS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfyTWM2OD1zND65OlEyKM7:TR?= NF\aNY1USU6JRWK=
PC-14 NIXEOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInY[W5KSzVyPUG0Mlk3PTRizszN NVrMbHBxW0GQR1XS
D-283MED MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr3[nE6UUN3ME2xOU4xOTFzIN88US=> MmXEV2FPT0WU
OE19 NVfXfFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF3LkG1OFEh|ryP M3rMVHNCVkeHUh?=
CAS-1 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLTRVJKSzVyPUG1MlQyQDRizszN MV\TRW5ITVJ?
NCI-H727 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq2SHJOUUN3ME2xOU41OjJzIN88US=> NGXJZ4VUSU6JRWK=
SiHa NFO1ZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{faWWlEPTB;MUWuO|U6PCEQvF2= M3PiVHNCVkeHUh?=
BFTC-905 M13RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG2ZVRyUUN3ME2xOU44Pjl2IN88US=> NFW4TGZUSU6JRWK=
MDA-MB-453 NHHUOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjUeHpKSzVyPUG2MlE3PDJizszN NH;3c4dUSU6JRWK=
HuP-T3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4np[WlEPTB;MU[uOlM4OyEQvF2= MULTRW5ITVJ?
SK-LU-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF4Lk[5OVYh|ryP NGLoWWhUSU6JRWK=
Detroit562 NF65NGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\xeGlKSzVyPUG2Mlc{OThizszN NEPGTYNUSU6JRWK=
HCC1569 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPkSI9KSzVyPUG2Mlg{OzdizszN NIrYU3ZUSU6JRWK=
SK-MES-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\tdpRKSzVyPUG2Mlg1OTlizszN NGrPcm9USU6JRWK=
BB65-RCC NW[0bYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;JemlEPTB;MUeuNFQ4QSEQvF2= NGrwfmxUSU6JRWK=
LOXIMVI NFrKbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnzUFZOUUN3ME2xO{4xPzB5IN88US=> Mn;FV2FPT0WU
SW1783 NYGxOmtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF5LkGyPEDPxE1? M4TkXXNCVkeHUh?=
NH-12 M3HHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:zTWM2OD1zNz6zN|A{KM7:TR?= NXrmblV6W0GQR1XS
UACC-257 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[xTmlEPTB;MUeuOVUyOiEQvF2= MUTTRW5ITVJ?
KOSC-2 NXjCbIVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjRW3JSUUN3ME2xO{43PzV5IN88US=> NVjLeGZlW0GQR1XS
KG-1 NYTVboRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn6do5LUUN3ME2xO{43QTN5IN88US=> M2i2VnNCVkeHUh?=
M059J MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDaeYdKSzVyPUG3MlcxOyEQvF2= MXHTRW5ITVJ?
MHH-NB-11 M1PLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHEcVFKSzVyPUG3Mlk3PzNizszN NF3sVVlUSU6JRWK=
EW-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\oenJVUUN3ME2xPE4yOzh{IN88US=> NGr1WYpUSU6JRWK=
CAL-85-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF6LkKzOVch|ryP MX3TRW5ITVJ?
639-V M4HCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fYeWlEPTB;MUiuN|M2PCEQvF2= MYLTRW5ITVJ?
C32 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rXemlEPTB;MUiuOFczPyEQvF2= MkmxV2FPT0WU
KM-H2 M{PEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\0UoVKSzVyPUG4MlUzOzJizszN NGXyVlBUSU6JRWK=
A253 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K3VWlEPTB;MUiuO|I5PiEQvF2= NXO3VnA3W0GQR1XS
NCI-N87 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KzVGlEPTB;MUiuPVAxQCEQvF2= NWK0Npg6W0GQR1XS
8-MG-BA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3ydG1lUUN3ME2xPU4xPjR4IN88US=> NF32eVdUSU6JRWK=
GI-ME-N NUT4eJR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TJUWlEPTB;MUmuNVU1PiEQvF2= NHnJdpRUSU6JRWK=
8305C MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O3W2lEPTB;MUmuNlI5PiEQvF2= MnrkV2FPT0WU
TE-8 NUS4Sm1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHsSFA2UUN3ME2xPU4{ODJ2IN88US=> M1;DSHNCVkeHUh?=
KYSE-270 NIH1fFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfYWWpiUUN3ME2yNE4xOjF5IN88US=> Moe5V2FPT0WU
HL-60 NX\tbJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJyLkC5OFEh|ryP MWLTRW5ITVJ?
Mo-T Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfiVodKSzVyPUKwMlE3PjVizszN NVXBTGt3W0GQR1XS
NCI-H1355 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\WTWM2OD1{MD6zN|c1KM7:TR?= NUDLNZpiW0GQR1XS
HT-1080 NFewc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nzcGlEPTB;MkCuOVQ6PyEQvF2= M{jEVHNCVkeHUh?=
MIA-PaCa-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJyLk[4PFMh|ryP MlS0V2FPT0WU
NCI-H441 M3z5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3EWWdGUUN3ME2yNE44Ozd7IN88US=> M4HqcHNCVkeHUh?=
LCLC-97TM1 NWe1e5FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke1TWM2OD1{MD64NVM1KM7:TR?= MYHTRW5ITVJ?
HT-3 M4PoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nCcmlEPTB;MkGuOVY{OSEQvF2= MX;TRW5ITVJ?
22RV1 M3nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn2fG9[UUN3ME2yNU42Pjh3IN88US=> NGjYfpNUSU6JRWK=
LK-2 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJzLkW5OVMh|ryP M2XEc3NCVkeHUh?=
CW-2 M2Tm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjTXopwUUN3ME2yNU43ODZ7IN88US=> MkDnV2FPT0WU
KYSE-510 M1v4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrvWGFKSzVyPUKxMlYxQTVizszN MULTRW5ITVJ?
CGTH-W-1 M2jrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJzLkexOlYh|ryP MkDQV2FPT0WU
NCI-H661 NXLQcGhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7CNFZ2UUN3ME2yNk4xOzRizszN MVLTRW5ITVJ?
KU-19-19 NFr4VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;HUXhKSzVyPUKyMlE3QTdizszN MmDTV2FPT0WU
NCI-H2122 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ{LkK0N|Ih|ryP M{TXfXNCVkeHUh?=
NCI-H526 NHfVTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ{LkO4PVUh|ryP NVXPR4M1W0GQR1XS
NCI-H1650 NVnGe4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjPOnZKSzVyPUKyMlc3PCEQvF2= MWDTRW5ITVJ?
AM-38 NHjrTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfOdmNKSzVyPUKyMlg3QDlizszN NFm4W4FUSU6JRWK=
NCI-H2405 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[5ZlZHUUN3ME2yN{4zPTN|IN88US=> MULTRW5ITVJ?
M14 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ|LkSwPFgh|ryP NIG4VY5USU6JRWK=
ES4 NUjt[VQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TtNGlEPTB;MkOuOFI{OiEQvF2= MmfmV2FPT0WU
DJM-1 NFzVZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LifGlEPTB;MkOuOVI{PCEQvF2= NVPUPW9jW0GQR1XS
S-117 M2rKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXxdFFKSzVyPUKzMlc3PTFizszN MVPTRW5ITVJ?
MZ2-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\NUVZKSzVyPUKzMlc4PTlizszN MXjTRW5ITVJ?
SK-MEL-2 NWHwO2NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXnbZpwUUN3ME2yN{45OTN|IN88US=> MVnTRW5ITVJ?
HCC1806 NVjZV2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPoe5RKSzVyPUKzMlg4ODlizszN MVzTRW5ITVJ?
NMC-G1 NGLlelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TqSmlEPTB;MkSuNlIzPiEQvF2= M2fJWnNCVkeHUh?=
DK-MG M{\we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULLOYd3UUN3ME2yOE4zQTRizszN MV7TRW5ITVJ?
SK-N-FI NEfrfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ2LkOzNFIh|ryP NVrWS284W0GQR1XS
KINGS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[5TWM2OD1{ND60PFc1KM7:TR?= NUnqTHRQW0GQR1XS
HCC2998 NHu0fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjMfVFKSzVyPUK0MlQ5QDVizszN M4qyTXNCVkeHUh?=
ALL-PO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ2Lk[xPUDPxE1? MXzTRW5ITVJ?
MPP-89 NHTDZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkToTWM2OD1{NT6wOFU5KM7:TR?= NU\qSHZ[W0GQR1XS
NCI-H2342 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zFNWlEPTB;MkWuNVk2OyEQvF2= MlL4V2FPT0WU
TE-1 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36OYFKSzVyPUK1MlM2PjNizszN NFT0NIZUSU6JRWK=
RH-18 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrCTWM2OD1{NT61PVE5KM7:TR?= MVTTRW5ITVJ?
HT-1376 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13oeWlEPTB;MkWuOlQ3PSEQvF2= NHPWfYtUSU6JRWK=
U-2-OS MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ3Lk[4PFgh|ryP M4rpPXNCVkeHUh?=
BT-549 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ3LkmwNVEh|ryP NVnrdpQ1W0GQR1XS
NCI-H1755 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTmcGZKSzVyPUK1Mlk6PDVizszN MXXTRW5ITVJ?
EW-13 NX\wVIozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD1{Nj6wNlc1KM7:TR?= Ml62V2FPT0WU
NB13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr2bIJWUUN3ME2yOk4xQTR7IN88US=> Moi5V2FPT0WU
NUGC-3 NWS4boRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ4LkKxNFMh|ryP NF\1OJdUSU6JRWK=
GMS-10 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ4LkKzOVMh|ryP MlXOV2FPT0WU
CHP-134 NYnqe5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCwb41qUUN3ME2yOk4{QDZ5IN88US=> NGP2fpZUSU6JRWK=
SW962 NHTnZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LWVWlEPTB;Mk[uOVAzOSEQvF2= M1;PRnNCVkeHUh?=
SNU-449 M1nOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPOTnl[UUN3ME2yO{4xQDB|IN88US=> MmTLV2FPT0WU
HuP-T4 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3wTWM2OD1{Nz6wPFc6KM7:TR?= MXTTRW5ITVJ?
SW948 NHjxT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHoTJBKSzVyPUK3MlE{PDRizszN MWrTRW5ITVJ?
NCI-H226 NUDzN|VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrZPXdKSzVyPUK3MlQ2PzhizszN Mn3NV2FPT0WU
SK-PN-DW MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf6WpZKSzVyPUK3MlYxOTJizszN NWfBd5ROW0GQR1XS
GI-1 NYn1ZYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HSPGlEPTB;MkeuO|IyKM7:TR?= MlfzV2FPT0WU
CAL-12T NH\LWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTkTWM2OD1{OD6xNVEzKM7:TR?= MorLV2FPT0WU
YAPC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjVTWM2OD1{OD6yOVY1KM7:TR?= MX\TRW5ITVJ?
SNU-C2B NWTHbGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLSN4V2UUN3ME2yPE4zQTZ2IN88US=> NFHBUW1USU6JRWK=
RCC10RGB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnFcHRTUUN3ME2yPE42PDF5IN88US=> M3fEdnNCVkeHUh?=
ES7 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL2UItKSzVyPUK5MlE1PjVizszN NXy3WGZsW0GQR1XS
PANC-03-27 NH;OWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[1TWM2OD1{OT60OFQh|ryP MoTnV2FPT0WU
ES6 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILrU3RKSzVyPUK5MlgyPTdizszN NInuR|JUSU6JRWK=
HT-1197 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnWTWM2OD1|MD6wOVk5KM7:TR?= NGWyeZRUSU6JRWK=
ZR-75-30 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljLTWM2OD1|MD6yN|g{KM7:TR?= NXLCNW96W0GQR1XS
DB NV62UJprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXGcpZKSzVyPUOwMlQ6PDJizszN M1PZTnNCVkeHUh?=
OCI-AML2 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nqemlEPTB;M{GuNFY6KM7:TR?= NH\PeYhUSU6JRWK=
NCI-H2170 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjBVZRkUUN3ME2zNU45PTF4IN88US=> NX;kPW9{W0GQR1XS
IST-MES1 NWfYR2RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLVTWM2OD1|Mj6yPFk4KM7:TR?= NWL2UpppW0GQR1XS
769-P NGPiZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i5OmlEPTB;M{KuN|Y1OSEQvF2= Mki4V2FPT0WU
COR-L23 M3LROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjPXmpKSzVyPUOyMlkxPzNizszN NETEVGlUSU6JRWK=
SW626 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN|LkG3O|Yh|ryP MnTDV2FPT0WU
LU-139 NYjBOlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrvTWM2OD1|Mz62OlA2KM7:TR?= NVPPSnhJW0GQR1XS
HT-144 M1jBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTN|Lki2N{DPxE1? NWjsVHdGW0GQR1XS
CaR-1 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jDZmlEPTB;M{OuPVgzOiEQvF2= M3zS[nNCVkeHUh?=
OE33 NXLFcI8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN2LkK4OVUh|ryP NIPvSGJUSU6JRWK=
COLO-800 NEnZWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvWUIFiUUN3ME2zOE4{PjR5IN88US=> Mkj5V2FPT0WU
NB14 NIj4UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH73eZBKSzVyPUO0MlQ3QDRizszN MWfTRW5ITVJ?
KURAMOCHI NVvwblI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN4LkGxPVgh|ryP NWnYW4xtW0GQR1XS
SW48 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW5TWM2OD1|Nj6yOFc1KM7:TR?= M{HPZnNCVkeHUh?=
Daoy MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO2T4FuUUN3ME2zOk43PTN6IN88US=> MlfnV2FPT0WU
TGBC24TKB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\USJlKSzVyPUO2MlY4KM7:TR?= NH7JO2pUSU6JRWK=
DU-4475 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX73T5lPUUN3ME2zOk46ODN|IN88US=> M2XwV3NCVkeHUh?=
SW1417 M4jQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17UU2lEPTB;M{iuNFU2OiEQvF2= MVHTRW5ITVJ?
EFO-21 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjlVlBKSzVyPUO4Mlk{PDlizszN M1qzZnNCVkeHUh?=
MG-63 NWWzO4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviTWM2OD1|OT6zOFI1KM7:TR?= MnjyV2FPT0WU
LC-2-ad Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHMVI9tUUN3ME2zPU42PTF{IN88US=> NGLhOlJUSU6JRWK=
NOMO-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjle5lKSzVyPUO5MlgzPzRizszN MUfTRW5ITVJ?
COLO-741 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRyLkGzNFQh|ryP M4fP[nNCVkeHUh?=
BxPC-3 M1\kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRyLkW2PFYh|ryP MVjTRW5ITVJ?
HSC-2 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y1PGlEPTB;NECuPVEyOyEQvF2= NYPPbIZGW0GQR1XS
UMC-11 NH;JR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rKZmlEPTB;NEGuNlY{KM7:TR?= MoDMV2FPT0WU
HCC1937 NWj4bpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO2[pdKSzVyPUSyMlc5PDNizszN MnTVV2FPT0WU
Calu-6 NYDnXYU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTR|LkKzPFIh|ryP MVPTRW5ITVJ?
NCI-H1573 NUnWNIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR|LkO0O|ch|ryP NEL2S2ZUSU6JRWK=
SK-N-AS MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ztTWlEPTB;NEOuOlAyQSEQvF2= NVfjfnQzW0GQR1XS
PSN1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfaTWM2OD12NT6yOVQ5KM7:TR?= NHnyelFUSU6JRWK=
TE-11 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTR3LkS4OFIh|ryP NF;CdYFUSU6JRWK=
NCI-H1155 NEDmcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7sUnVKSzVyPUS1Mlg6PjdizszN NF;tO5VUSU6JRWK=
KM12 NVzmV2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\CNVBKSzVyPUS1MlkxPzZizszN MX;TRW5ITVJ?
RO82-W-1 NUHndml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn0VoZuUUN3ME20Ok46QDJ{IN88US=> M{C5VXNCVkeHUh?=
SW1573 M2jPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[wU5R{UUN3ME20O{4{PzN4IN88US=> MUDTRW5ITVJ?
CAKI-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLFTWM2OD12OD6yPFQ2KM7:TR?= MY\TRW5ITVJ?
U-118-MG NXz0WnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS0RphyUUN3ME20PE4{PzB{IN88US=> NFnrSmFUSU6JRWK=
KYSE-520 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR6LkSwNVYh|ryP NHrpXXhUSU6JRWK=
HT55 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTR7LkG0O|Qh|ryP M4\vVXNCVkeHUh?=
ChaGo-K-1 NFK1Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzESlVYUUN3ME20PU41Pzl|IN88US=> M3zD[XNCVkeHUh?=
IA-LM MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TTT2lEPTB;NUSuOlMzOiEQvF2= MWLTRW5ITVJ?
UACC-62 NELPZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m3eGlEPTB;NUWuNVA1PiEQvF2= MnjLV2FPT0WU
MKN7 NIfmZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jLUWlEPTB;NU[uNFI5PSEQvF2= Moq3V2FPT0WU
HPAF-II MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3yTWM2OD13Nj60NFc{KM7:TR?= Mo\RV2FPT0WU
NTERA-S-cl-D1 M2DTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n5eGlEPTB;NUeuO|c5KM7:TR?= NIHxWXpUSU6JRWK=
FTC-133 M2nBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLFUIZ3UUN3ME21PE4xQTZ7IN88US=> NE\zXpdUSU6JRWK=
MHH-ES-1 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGyTWM2OD13OD60PFE1KM7:TR?= M{jpNHNCVkeHUh?=
JVM-2 M{nLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\pcmd6UUN3ME21PE46PTB4IN88US=> MY\TRW5ITVJ?
TCCSUP M124TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;TdXdKSzVyPUW5MlUzPzlizszN NVjOWZVkW0GQR1XS
COLO-824 M3H1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjkTWM2OD14MD6wO|E6KM7:TR?= Mnq5V2FPT0WU
647-V MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17JSWlEPTB;NkCuNVM1PyEQvF2= Mo\0V2FPT0WU
HD-MY-Z MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPt[IxOUUN3ME22NE42Ojl2IN88US=> MlnFV2FPT0WU
LS-411N M2DL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTCcmpKSzVyPU[xMlM6ODNizszN MWDTRW5ITVJ?
NCI-H596 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTPTWM2OD14Mj63OFk3KM7:TR?= NELOfIhUSU6JRWK=
C-33-A NFT0b3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7LXWJKSzVyPU[0MlA6PTdizszN NE[5WpZUSU6JRWK=
BHY NF2yZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTZ2LkGyOFUh|ryP MULTRW5ITVJ?
KGN MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD14ND61OVE1KM7:TR?= MUfTRW5ITVJ?
NCI-H1092 M4L5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTwW41JUUN3ME22OU4xODl3IN88US=> MV;TRW5ITVJ?
MZ1-PC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f4RWlEPTB;NkWuOVY1QSEQvF2= NXKzeFVvW0GQR1XS
LB831-BLC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7xTWM2OD14NT64OFgyKM7:TR?= NXXpfItMW0GQR1XS
SW620 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTZ4LkKwN|kh|ryP M{flXnNCVkeHUh?=
HuO-3N1 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rzRmlEPTB;NkiuN|I{QCEQvF2= MnmzV2FPT0WU
SK-HEP-1 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonjTWM2OD14OT65OFg3KM7:TR?= NUHJd|R{W0GQR1XS
LCLC-103H MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojnTWM2OD15MD62O|A2KM7:TR?= NULEd5J[W0GQR1XS
KYSE-70 M3zhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPmTWM2OD15MD63PFM2KM7:TR?= NHjiUoxUSU6JRWK=
Mewo NGPnXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTdzLkWwOUDPxE1? NHrCdW5USU6JRWK=
COLO-668 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jIRWlEPTB;N{GuPFQ2OSEQvF2= M3PyUXNCVkeHUh?=
NCI-H522 M1naRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;VfWhPUUN3ME23Nk4{PDF|IN88US=> NYG2S2RUW0GQR1XS
NCI-H1437 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PPWmlEPTB;N{SuOFA1QCEQvF2= NXfVZoxPW0GQR1XS
U-266 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELLbmNKSzVyPUe1MlQ2OTZizszN NHHDW3hUSU6JRWK=
MC116 M1jPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu4R|RRUUN3ME23OU42PzB6IN88US=> NH3vXnJUSU6JRWK=
PANC-10-05 NG\Bd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTd5LkSyOFMh|ryP NX3PRplqW0GQR1XS
KYSE-180 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;acldKSzVyPUe3MlU1PTRizszN NYDFUm1QW0GQR1XS
JAR NIHZTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDQS2VUUUN3ME23PU4xPTR4IN88US=> MoHZV2FPT0WU
CAL-62 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThyLkC5OUDPxE1? M2XYOXNCVkeHUh?=
A3-KAW NF36dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L0TWlEPTB;OECuNlE2PCEQvF2= MUDTRW5ITVJ?
PANC-08-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfERYZQUUN3ME24NU4yPzZ6IN88US=> MVrTRW5ITVJ?
HSC-3 M1XnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWiwVY9{UUN3ME24N{4{ODdzIN88US=> MX3TRW5ITVJ?
HTC-C3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTh|LkS3NFIh|ryP NELIfo5USU6JRWK=
KY821 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPyTWM2OD16ND6wPFkzKM7:TR?= MoX4V2FPT0WU
DoTc2-4510 M3G5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTh2LkKxPFUh|ryP NW\KW4s1W0GQR1XS
NCI-H1581 M4qwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP6TWM2OD16NT60OlQyKM7:TR?= M{DtN3NCVkeHUh?=
KARPAS-299 NHfOTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\oWWlEPTB;OE[uNVk4PyEQvF2= NU\ZfJdbW0GQR1XS
IST-MEL1 NEXxUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvsb3BKSzVyPUi2Mlg5PzJizszN M4\mR3NCVkeHUh?=
KP-N-YS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTh7LkmwNlgh|ryP NVT5RXg3W0GQR1XS
KYSE-410 NW[zdoRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ubmlEPTB;OUGuOFA1OiEQvF2= NHHmT45USU6JRWK=
TE-10 NW\OfndLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTlzLkW2NVEh|ryP MUDTRW5ITVJ?
SK-MEL-1 M3HFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7xOnk5UUN3ME25Nk46OTB4IN88US=> MV7TRW5ITVJ?
COLO-792 NFrLeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nGUGlEPTB;OUWuNlU3PCEQvF2= M2T5UnNCVkeHUh?=
SCH M3rkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTl4LkO4O|ch|ryP NXLlbINxW0GQR1XS
NCI-H1792 NGq0[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;VTWM2OD17Nj64PVkzKM7:TR?= MXvTRW5ITVJ?
NCI-H2029 NUHkNIV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHmfI9SUUN3ME25Ok46PTZ4IN88US=> MlzNV2FPT0WU
SW684 NXXiXFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfKb5JSUUN3ME25PE43PjV2IN88US=> NITnXIxUSU6JRWK=
NCI-H209 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXPUnRKSzVyPUGwNE4yOjFizszN MWLTRW5ITVJ?
HLE M2fmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH4TWM2OD1zMEWuNlgzKM7:TR?= MVjTRW5ITVJ?
GOTO M{ny[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DlVmlEPTB;MUC3Mlc4PyEQvF2= MnH4V2FPT0WU
NCI-H1793 NV:xOZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[yWmlEPTB;MUC5MlI5KM7:TR?= NEXUS2dUSU6JRWK=
D-392MG NYHCT|dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnGe45KSzVyPUGxO{4{QThizszN M{TmbHNCVkeHUh?=
SW1990 NU\aZndkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjoelFFUUN3ME2xNlAvQTVzIN88US=> MnLKV2FPT0WU
ML-2 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH71ZpNKSzVyPUGyNU43PzZizszN M2PNNnNCVkeHUh?=
NCI-H2452 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe2WlZKSzVyPUGyNk4zOSEQvF2= Ml;xV2FPT0WU
SK-MEL-30 NHzLNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnSTWM2OD1zMkOuNlQ1KM7:TR?= Mlr3V2FPT0WU
SN12C M4XsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1roS2lEPTB;MUK0MlE4PiEQvF2= Mni0V2FPT0WU
NCI-H1770 M3izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF{NT61NVQh|ryP MUnTRW5ITVJ?
SF268 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF{Nj6xOVgh|ryP NYnCem9PW0GQR1XS
BALL-1 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK2ZmM2UUN3ME2xNlYvOjNizszN M3z6UnNCVkeHUh?=
COLO-679 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDETWM2OD1zMk[uO|U{KM7:TR?= NIrQfIlUSU6JRWK=
A2780 M1HVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{OD65PFgh|ryP MV3TRW5ITVJ?
NCI-H1651 NFzhdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjTWM2OD1zM{GuNlQ{KM7:TR?= NHTrSllUSU6JRWK=
NCI-H2087 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnzTWM2OD1zM{GuOFg{KM7:TR?= NHvaboFUSU6JRWK=
U-87-MG M4HWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvZZXdNUUN3ME2xN|MvPjB2IN88US=> NIfNSHNUSU6JRWK=
LB2518-MEL NXv0TXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PUOGlEPTB;MUO1Mlk6OyEQvF2= NEDVflBUSU6JRWK=
HCT-116 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPw[GtvUUN3ME2xN|cvOjF5IN88US=> Moe5V2FPT0WU
Ca9-22 NFzXW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;kT2lEPTB;MUO5Mlg{OyEQvF2= M4nBWnNCVkeHUh?=
COR-L88 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yc4NiUUN3ME2xOFIvOTRizszN MX7TRW5ITVJ?
CP50-MEL-B NWnYNmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf5WnhKSzVyPUG0OE42ODFizszN NWGzdZJHW0GQR1XS
OVCAR-8 NEDDbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTSTWM2OD1zNEWuOlM3KM7:TR?= M3HSVHNCVkeHUh?=
SK-MEL-3 M4XaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTzTWM2OD1zNEeuPFc5KM7:TR?= NFP4N3VUSU6JRWK=
GT3TKB NVTLVVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\GdGlEPTB;MUS5MlkzQCEQvF2= MVvTRW5ITVJ?
KYSE-450 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3MT61N|kh|ryP MY\TRW5ITVJ?
CAPAN-1 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF3Mz6wOlQh|ryP MYfTRW5ITVJ?
BEN M4m0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG5TWM2OD1zNUOuPVI5KM7:TR?= MUjTRW5ITVJ?
NCI-H1304 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF3ND62PVQh|ryP MXnTRW5ITVJ?
KU812 NHX1[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF3OD62O|Qh|ryP M1H6TXNCVkeHUh?=
Capan-2 NYrLTYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmwTWM2OD1zNkCuOVU{KM7:TR?= MXHTRW5ITVJ?
A673 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDU[3dQUUN3ME2xOlEvPzB3IN88US=> MojpV2FPT0WU
SAS MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqfmlEPTB;MU[yMlY4QCEQvF2= NVX4RYQ{W0GQR1XS
NY NFiySHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TOe2lEPTB;MU[1MlMyPCEQvF2= MlrrV2FPT0WU
HCE-4 NICxW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF4Nj64OFUh|ryP MmrQV2FPT0WU
MDA-MB-231 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPaRmxKSzVyPUG3O{42ODNizszN NEHGephUSU6JRWK=
no-10 NXXzSHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF5OD6xN|Qh|ryP MXHTRW5ITVJ?
MZ7-mel NHvhdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfRWYxKSzVyPUG3PE41PjdizszN NFTh[G5USU6JRWK=
NCI-H82 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojOTWM2OD1zOECuNVY2KM7:TR?= NXu5[G4yW0GQR1XS
CAL-72 NYXMW5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDpUZZKSzVyPUG4OU4xPTRizszN MlHQV2FPT0WU
NCI-SNU-5 NYKw[WZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnwUllOUUN3ME2xPFYvQDRizszN MUjTRW5ITVJ?
OVCAR-4 NHPOOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF6OD6zN|Mh|ryP M1nzbXNCVkeHUh?=
SCC-9 NVvodIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;FTWM2OD1zOUGg{txO NFXXd5FUSU6JRWK=
KYSE-150 M1HGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;LdppiUUN3ME2xPVEvQDh6IN88US=> MnzXV2FPT0WU
HT-29 NXy3WIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJyMT6yNVIh|ryP MWjTRW5ITVJ?
COLO-678 M4fTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX5V4lKSzVyPUKwNU41PSEQvF2= M2nZWHNCVkeHUh?=
NCI-H650 NHOy[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPBUXk2UUN3ME2yNFIvOTB|IN88US=> NVSzXno3W0GQR1XS
HuCCT1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzkTWM2OD1{MESuNlA5KM7:TR?= NEXFR3BUSU6JRWK=
SW1116 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjteYtOUUN3ME2yNFcvODd5IN88US=> MWTTRW5ITVJ?
DBTRG-05MG MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nUmlEPTB;MkC3MlkxQSEQvF2= MnfuV2FPT0WU
SW982 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDvTWM2OD1{MEeuPVQ5KM7:TR?= Mo\PV2FPT0WU
RCM-1 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLoOFZKSzVyPUKxOE44PjJizszN M3TOVnNCVkeHUh?=
COLO-320-HSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKyTWM2OD1{MU[uNVI2KM7:TR?= MUTTRW5ITVJ?
KNS-42 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK5TWM2OD1{MU[uOVc1KM7:TR?= MWnTRW5ITVJ?
C2BBe1 NEe2b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvHTWM2OD1{M{GuPVA2KM7:TR?= NX3EemR[W0GQR1XS
CCRF-CEM M4W3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HMNmlEPTB;MkSzMlc6PSEQvF2= Ml;3V2FPT0WU
SH-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrJ[GNKSzVyPUK0Ok4xQSEQvF2= NEfvUFJUSU6JRWK=
LS-1034 M4fWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvQTWM2OD1{NE[uNlY3KM7:TR?= NH;vVJVUSU6JRWK=
NCI-H2347 NWjoUJpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXjOJVKSzVyPUK0O{44OTNizszN NIG4UGFUSU6JRWK=
RPMI-8866 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nGdmlEPTB;MkS5MlI4KM7:TR?= NX7VbZN{W0GQR1XS
GAK MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH5R2d6UUN3ME2yOVMvODB{IN88US=> M1nkZnNCVkeHUh?=
NB6 NYP5TVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\qTWM2OD1{N{CuNUDPxE1? NHLkR45USU6JRWK=
COLO-680N MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjBfG9EUUN3ME2yO|IvPTJ5IN88US=> NGDnO25USU6JRWK=
RERF-LC-MS NF[5NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn1TWM2OD1{N{[uNFA4KM7:TR?= NIjGdopUSU6JRWK=
TGBC11TKB MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJ5OD6xO|gh|ryP Mn7EV2FPT0WU
C8166 M{LZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnxTWM2OD1{N{iuOVA3KM7:TR?= M2DWWnNCVkeHUh?=
HDLM-2 M3;pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Ww[2lEPTB;Mkm0MlQxQSEQvF2= NGLOVGJUSU6JRWK=
IGR-1 NHv1O4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\pOWlEPTB;Mkm1MlY2QSEQvF2= NIX5WphUSU6JRWK=
FADU MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi3TWM2OD1{OUeuOVEh|ryP MoHGV2FPT0WU
L-428 NHSyRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu5clVKSzVyPUK5O{43OTZizszN Mo\mV2FPT0WU
LU-65 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ZO45KSzVyPUOwOE4{OiEQvF2= MWrTRW5ITVJ?
HEL M4XFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\jTWM2OD1|MEmuPVg{KM7:TR?= NXryVIJVW0GQR1XS
NCI-H810 M{jBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNzMD61O{DPxE1? M4\5VXNCVkeHUh?=
C3A MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;2eGlEPTB;M{GxMlgxOiEQvF2= MlLvV2FPT0WU
NCI-H630 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjRXIs3UUN3ME2zN|IvOjl2IN88US=> NFvNWYVUSU6JRWK=
KP-N-YN NVridZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnnTWM2OD1|NEGuNVI{KM7:TR?= MlfMV2FPT0WU
MOLT-13 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkdlFKSzVyPUO0Nk4{OjZizszN M3j2fHNCVkeHUh?=
NCI-H1993 NG\2[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN2Mj6zOlUh|ryP M1KzZnNCVkeHUh?=
BE-13 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LhZ2lEPTB;M{S0MlE3PyEQvF2= NY\1SWhmW0GQR1XS
IST-SL1 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKzVXRKSzVyPUO0O{41ODFizszN NHW2OmZUSU6JRWK=
TE-9 M3r6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN4Mz61PFkh|ryP M3LCc3NCVkeHUh?=
LU-135 NEPBbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPuTWM2OD1|NkeuNFM2KM7:TR?= M3f0[3NCVkeHUh?=
T84 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWqwc5hUUUN3ME2zO|QvPzF{IN88US=> MWPTRW5ITVJ?
K-562 NGHp[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\mTWM2OD1|OEOuN|Yh|ryP MoPtV2FPT0WU
SBC-5 M3TlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzGcWQ4UUN3ME2zPFYvQTh3IN88US=> MULTRW5ITVJ?
NB17 M3m2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzuZYdKSzVyPUO5Nk42QTZizszN Ml36V2FPT0WU
NCI-H2052 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTuTWM2OD1|OUiuOFczKM7:TR?= MofRV2FPT0WU
HCC38 NXjicIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\k[oxFUUN3ME20NFEvPTl|IN88US=> MU\TRW5ITVJ?
NCI-H69 NU\j[|RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu3TWM2OD12NEGuNFg{KM7:TR?= NYe5bJVRW0GQR1XS

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01263145 Completed Adult Solid Neoplasm|Recurrent Breast Carcinoma|Stage IV Breast Cancer National Cancer Institute (NCI) January 5 2011 Phase 1
NCT01239342 Active not recruiting Metastatic Renal Cell Cancer|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer National Cancer Institute (NCI)|M.D. Anderson Cancer Center January 27 2011 Phase 2
NCT01604772 Completed Recurrent Oral Cavity Adenoid Cystic Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Adenoid Cystic Carcinoma|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 National Cancer Institute (NCI) July 23 2012 Phase 2
NCT01480154 Active not recruiting Adult Solid Neoplasm|Hormone-Resistant Prostate Carcinoma|Recurrent Melanoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 National Cancer Institute (NCI) November 23 2011 Phase 1
NCT01251861 Active not recruiting Recurrent Prostate Carcinoma|Stage I Prostate Cancer AJCC v7|Stage IIA Prostate Cancer AJCC v7|Stage IIB Prostate Cancer AJCC v7|Stage III Prostate Cancer AJCC v7 National Cancer Institute (NCI) December 23 2010 Phase 2
NCT01021748 Completed Locally Advanced or Metastatic Solid Tumors Merck Sharp & Dohme Corp.|AstraZeneca November 23 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 : AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) : Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products4

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID